Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalmefene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 known ✓ | P41143 | 12/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 10/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 9/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.80 |
| ▸ | PKM | P14618 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalmefene SCHEMBL14124638 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL4556466 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL18827079 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12646154 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL18457569 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL18160036 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12945213 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL17168341 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12566030 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 | |
| Nalmefene SCHEMBL12233286 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1NR1I2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 14812 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101753-A1 | NALFURAFINE AND NALMEFENE AS KAPPA OPIOID RECEPTOR INACTIVATING THERAPEUTIC AGENTS | UNIVERSITY OF WASHINGTON (US) | 2026-05-15 | — | — | WO | claimed |
| US-12617816-B2 | Composition and method for in vivo assay of opioid receptors | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2026-05-05 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260076956-A1 | METHODS FOR REGRESSING OR REVERSING FIBROSIS AND/OR LIVER CIRRHOSIS IN A SUBJECT IN NEED THEREOF USING HIGH-DOSE NIACIN, OR A NIACIN ANALOG THEREOF | US GOV VETERANS AFFAIRS (US) | 2026-03-19 | — | — | US | claimed |
| US-12569478-B2 | Sequestration compounds for treatment of substance use disorder and uses thereof | CLEAR SCIENTIFIC, INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-20260060620-A1 | Self-Monitoring Based Wearable Apparatus And Related Method For Opioid Overdose Detection And Antidote Delivery | Ezer Enterprises LLC | 2026-03-05 | — | — | US | claimed |
| US-20260060611-A1 | Remote monitoring based wearable apparatus and related method for opioid overdose detection and antidote delivery | Ezer Enterprises LLC | 2026-03-05 | — | — | US | claimed |
| US-20260048072-A1 | PHARMACEUTICAL PREPARATION FOR INTRANASAL ADMINISTRATION AND PREPARATION METHOD THEREFOR | CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) | 2026-02-19 | — | — | US | claimed |
| EP-4694932-A2 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260041682-A1 | PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERY | OREXO AB (SE) | 2026-02-12 | — | — | US | claimed |
| EP-0250796-A2 | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-01-07 | — | — | EP | claimed |
| US-4692451-A | ADMINISTERING NARCOTIC ANTAGONIST | TRUSTEES OF TUFTS COLLEGE (US) | 1987-09-08 | — | — | US | claimed |
| US-4673679-A | ESTERS, CARBONATES, CARBAMATES, OR SULFONATES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-06-16 | — | — | US | claimed |
| US-4626539-A | WITH FATTY ACID PENETRATION AID AND PROPYLENE GLYCOL | E. I. DUPONT DE NEMOURS AND COMPANY (US) | 1986-12-02 | — | — | US | claimed |
| EP-0103636-A4 | USE OF OPIUM ANTAGONISTS FOR THE MANUFACTURE OF MEDICAMENTS FOR CONTROLLING GASTROINTESTINAL DYSMOTILITY. | UNIV ROCKEFELLER (US) | 1986-03-04 | — | — | EP | claimed |
| EP-0171742-A2 | Transdermal delivery of opioids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-02-19 | — | — | EP | claimed |
| US-4477457-A | Method for inducing anorexia using nalmetrene | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-16 | — | — | US | claimed |
| EP-0107855-A1 | Method for inducing anorexia | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-05-09 | — | — | EP | claimed |
| EP-0103636-A1 | USE OF OPIUM ANTAGONISTS FOR THE MANUFACTURE OF MEDICAMENTS FOR CONTROLLING GASTROINTESTINAL DYSMOTILITY. | UNIV ROCKEFELLER (US) | 1984-03-28 | — | — | EP | claimed |
| WO-1983003197-A1 | METHOD FOR CONTROLLING GASTROINTESTINAL DYSMOTILITY | UNIV ROCKEFELLER (US) | 1983-09-29 | — | — | WO | claimed |